(Q38722574)

English

Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.

scientific article published on 6 January 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28062698%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28062698%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Ralf Schwanbeck

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28062698%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Paul Whi Parren

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28062698%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Frank J Beurskens

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28062698%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Janine Schuurman

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28062698%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Thomas Valerius

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28062698%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

author name string

Annalina Tammen

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28062698%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Stefanie Derer

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28062698%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Thies Rösner

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28062698%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Anna Kretschmer

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28062698%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

language of work or name

0 references

publication date

6 January 2017

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28062698%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Journal of Immunology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28062698%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

198

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28062698%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28062698%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1585-1594

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28062698%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Complement: a key system for immune surveillance and homeostasis

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Complement is activated by IgG hexamers assembled at the cell surface

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

New perspectives on complement mediated immunotherapy

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells.

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Complement activation determines the therapeutic activity of rituximab in vivo.

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy.

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Engineered antibodies with increased activity to recruit complement

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Structure and clinical relevance of the epidermal growth factor receptor in human cancer

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Antibody-based immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Effector mechanisms of therapeutic antibodies against ErbB receptors

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII).

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Epidermal growth factor receptor targeting IgG3 triggers complement-mediated lysis of decay-accelerating factor expressing tumor cells through the alternative pathway amplification loop.

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechanisms of EGFR antibodies

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

A simple, robust and highly efficient transient expression system for producing antibodies

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Convergent solutions to binding at a protein-protein interface

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for Dimerization

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

The binding site for C1q on IgG

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1601268

21 January 2018

Identifiers

10.4049/JIMMUNOL.1601268

1 reference

https://api.fatcat.wiki/v0/release/yhldxz6r35curcxvk5snedfzmq

30 July 2022

based on heuristic

mapped directly with Wikidata item

release_yhldxz6r35curcxvk5snedfzmq

1 reference

https://api.fatcat.wiki/v0/release/yhldxz6r35curcxvk5snedfzmq

30 July 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

https://api.fatcat.wiki/v0/release/yhldxz6r35curcxvk5snedfzmq

30 July 2022

based on heuristic

mapped directly with Wikidata item

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38722574&oldid=1801406969"